NCT02935517View on ClinicalTrials.gov

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2026

Conditions
Achromatopsia
Interventions
BIOLOGICAL

AGTC-402

AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.

Trial Locations (6)

32607

VitreoRetinal Associates, Gainesville

33136

Bascom Palmer Eye Institute, Miami

45242

Cincinnati Eye Institute, Cincinnati

91120

Hadassah-Hebrew University Medical Center, Jerusalem

97239

Casey Eye Institute, Oregon Health and Sciences University, Portland

02114

Massachusetts Eye and Ear Infirmary, Boston

Sponsors
All Listed Sponsors
lead

Beacon Therapeutics

INDUSTRY

NCT02935517 - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) | Biotech Hunter | Biotech Hunter